Explore more publications!
Iowa Healthcare Reporter
Got News to Share?

Iowa Healthcare Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Iowa Healthcare Reporter.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on November 3, 2025

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors
November 3, 2025

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

Indeterminate GlobeNewswire
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
November 3, 2025

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Indeterminate GlobeNewswire
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
November 3, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Indeterminate GlobeNewswire
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
November 3, 2025

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

Indeterminate GlobeNewswire
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 3, 2025

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Indeterminate GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
November 3, 2025

Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025

Indeterminate GlobeNewswire
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
November 3, 2025

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

Indeterminate GlobeNewswire
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment
November 3, 2025

Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment

Indeterminate GlobeNewswire
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease
November 3, 2025

ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease

Indeterminate GlobeNewswire
Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
November 3, 2025

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Indeterminate GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
November 3, 2025

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Kailera Therapeutics Appoints Frank Clyburn to Board of Directors
November 3, 2025

Kailera Therapeutics Appoints Frank Clyburn to Board of Directors

Indeterminate GlobeNewswire
Apogee Therapeutics to Participate in Upcoming Conferences
November 3, 2025

Apogee Therapeutics to Participate in Upcoming Conferences

Indeterminate GlobeNewswire
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
November 3, 2025

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Indeterminate GlobeNewswire
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
November 3, 2025

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Indeterminate GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 3, 2025

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Indeterminate GlobeNewswire
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
November 3, 2025

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

Indeterminate GlobeNewswire
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
November 3, 2025

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Indeterminate GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 3, 2025

Dyne Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
November 3, 2025

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions